Literature DB >> 17100158

Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer.

A J Colquhoun1, S Sundar, P H Rajjayabun, T R L Griffiths, R P Symonds, J K Mellon.   

Abstract

AIMS: Epidermal growth factor receptor (EGFR) is expressed by over 70% of muscle-invasive bladder tumours and is associated with diminished overall survival. In model tumour systems, ionising radiation has been shown to activate EGFR, leading to cellular proliferation and is therefore a possible mechanism of underlying radioresistance. We carried out an immunohistochemical study relating the clinical outcome of patients receiving radical radiotherapy for muscle-invasive bladder cancer to tumour EGFR status.
MATERIALS AND METHODS: Archived paraffin-embedded tumours from 110 consecutive patients receiving radical radiotherapy for muscle-invasive bladder cancer between 1991 and 1997 were immunohistochemically stained for EGFR. Data were collected concerning the tumour stage and grade, the presence of ureteric obstruction, the response to radiotherapy at 3 months, local recurrence rates, metastatic spread and survival. Multivariate analysis of potential independent prognostic factors of impaired bladder cancer-specific survival was carried out using Cox's regression.
RESULTS: Of 110 tumours, 79 (72%) stained positively for EGFR. Of 87 patients undergoing the 3-month check cystoscopy, 60 (69%) had a positive response to radiotherapy. A positive response to radiotherapy correlated significantly with a negative EGFR status (chi(2) test, P = 0.05). Kaplan-Meier survival analysis revealed a trend towards improved bladder cancer-specific survival in EGFR-negative patients (Log-rank, P = 0.10). A lack of response to radiotherapy at 3 months, local recurrence, metastatic spread and the presence of ureteric obstruction were all independent prognostic factors for diminished bladder cancer-specific survival (Cox's regression: P = 0.009, P = 0.001, P = 0.04 and P = 0.005, respectively).
CONCLUSIONS: EGFR status predicts the local response to radiotherapy but does not provide prognostic utility in relation to overall or bladder cancer-specific survival. As EGFR status seems to be linked to the initial response to radiotherapy, its inhibition may be a means of enhancing the radio-responsiveness of these poor prognosis tumours. Colquhoun, A. J.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100158     DOI: 10.1016/j.clon.2006.08.003

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  4 in total

Review 1.  Growth factors and receptors as prognostic markers in urothelial carcinoma.

Authors:  Peter C Black; Colin P N Dinney
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

2.  Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.

Authors:  Yi Mu; Deyu Sun
Journal:  Med Sci Monit       Date:  2018-08-20

3.  Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer.

Authors:  Hussein M Khaled; Abeer A Bahnassy; Amira A Raafat; Abdel-Rahman N Zekri; Maha S Madboul; Nadia M Mokhtar
Journal:  BMC Cancer       Date:  2009-01-26       Impact factor: 4.430

Review 4.  Role of tyrosine kinases in bladder cancer progression: an overview.

Authors:  Amir Sadra Zangouei; Amir Hossein Barjasteh; Hamid Reza Rahimi; Majid Mojarrad; Meysam Moghbeli
Journal:  Cell Commun Signal       Date:  2020-08-14       Impact factor: 5.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.